A. Wengner

发表

The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation

S. Rankin, R. Furze, S. Pitchford, 2007, Blood.

A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy

Michael Erkelenz, H. Weinmann, A. Rottmann, 2022, Bioconjugate chemistry.

Derives de triazolopyridines

P. Lienau, G. Siemeister, M. Koppitz, 2010 .

CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis.

P. Petrow, R. Bräuer, U. Höpken, 2007, Arthritis and rheumatism.

Therapeutic targeting of ATR in alveolar rhabdomyosarcoma

M. Selbach, P. Mertins, K. Haase, 2022, Nature Communications.

neutrophil mobilization during acute inflammation The coordinated action of G-CSF and ELR + CXC chemokines in

S. Rankin, S. Pitchford, A. Wengner, 2010 .

Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models

A. Kühl, K. Haase, J. Schulte, 2022, bioRxiv.

Degradation of oxidized extracellular proteins by microglia.

T. Grune, A. Stolzing, A. Wengner, 2002, Archives of biochemistry and biophysics.

mucosal tissue integrity CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed

H. Stein, C. Loddenkemper, U. Höpken, 2013 .

CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrity.

H. Stein, C. Loddenkemper, U. Höpken, 2007, Blood.

Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.

M. Meyerson, S. Schreiber, H. Greulich, 2019, ACS medicinal chemistry letters.

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Julia M. Schulze, H. Briem, P. Lienau, 2013, ChemMedChem.

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

P. Lienau, G. Siemeister, K. Ziegelbauer, 2012, Molecular Cancer Therapeutics.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

H. Briem, P. Lienau, U. Klar, 2020, Journal of medicinal chemistry.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

P. Lienau, O. von Ahsen, U. Klar, 2016, Molecular Cancer Therapeutics.

Targeting DNA Damage Response in Prostate and Breast Cancer

B. Haendler, A. Scholz, A. Wengner, 2020, International journal of molecular sciences.

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.

M. Lange, K. Ziegelbauer, D. Mumberg, 2017, Cancer cell.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

P. Lienau, D. Mumberg, C. Lange, 2017, Cancer letters.

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

S. Pileri, L. Cascione, A. Stathis, 2023, bioRxiv.

First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

Y. Drew, R. Plummer, A. Schlicker, 2020, Cancer discovery.

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

B. Goh, F. Meric-Bernstam, D. Hong, 2019, Journal of Clinical Oncology.

IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies

Michael Erkelenz, A. Sommer, D. Mumberg, 2020, Cancers.

Cover Picture: The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer (ChemMedChem 7/2013)

Julia M. Schulze, H. Briem, P. Lienau, 2013 .

Differential mobilization of subsets of progenitor cells from the bone marrow.

S. Rankin, S. Pitchford, A. Wengner, 2009, Cell stem cell.

Discovery of BAY-985 a highly selective TBK1/Ikkε inhibitor.

F. Prinz, H. Briem, D. Panne, 2019, Journal of medicinal chemistry.

Abstract 3883: Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models

P. Lienau, G. Siemeister, K. Ziegelbauer, 2010 .

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

A. Schlicker, P. Lienau, B. Haendler, 2019, Molecular Cancer Therapeutics.

Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus

G. Kempermann, S. Wolf, T. Kammertoens, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Targeted thorium-227 conjugates as treatment options in oncology

J. Karlsson, S. Hammer, A. Cuthbertson, 2023, Frontiers in Medicine.

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

H. Briem, P. Lienau, S. Hammer, 2021, Journal of medicinal chemistry.

Abstract 1393: PSMA-Targeted Thorium Conjugate (BAY 2315497) and olaparib combination show synergistic anti-tumor activity in prostate cancer models

S. Hammer, D. Mumberg, A. Scholz, 2021, Experimental and Molecular Therapeutics.

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

J. Karlsson, G. Siemeister, V. Cruciani, 2019, The Journal of Nuclear Medicine.

Preclinical Combination Studies of an FGFR2 Targeted Thorium Conjugate and the ATR Inhibitor BAY 1895344.

J. Karlsson, H. Ellinger-Ziegelbauer, A. Sommer, 2019, International journal of radiation oncology, biology, physics.

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition

T. Tan, A. Jeyasekharan, D. Lim, 2022, The Journal of pathology.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

H. Briem, P. Lienau, U. Luecking, 2020, Journal of medicinal chemistry.

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

M. Selbach, K. Haase, Koshi Imami, 2020, bioRxiv.

Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

B. Ploeger, A. Wengner, A. Wiedmann, 2022, European Journal of Cancer.

Identification of a gene cluster encoding an arginine ATP-binding-cassette transporter in the genome of the thermophilic Gram-positive bacterium Geobacillus stearothermophilus strain DSMZ 13240.

F. Scheffel, E. Schneider, A. Wengner, 2005, Microbiology.

Differential mobilization of subsets of progenitor cells from the bone marrow.

S. Rankin, S. Pitchford, A. Wengner, 2009, Cell stem cell.

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.

M. Lange, K. Ziegelbauer, D. Mumberg, 2017, Cancer cell.

Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL

O. Politz, M. Lange, K. Ziegelbauer, 2018, Experimental and Molecular Therapeutics.